MX2018000213A - Metodos para tratar el vhc. - Google Patents

Metodos para tratar el vhc.

Info

Publication number
MX2018000213A
MX2018000213A MX2018000213A MX2018000213A MX2018000213A MX 2018000213 A MX2018000213 A MX 2018000213A MX 2018000213 A MX2018000213 A MX 2018000213A MX 2018000213 A MX2018000213 A MX 2018000213A MX 2018000213 A MX2018000213 A MX 2018000213A
Authority
MX
Mexico
Prior art keywords
therapies
methods
treating hcv
administration
hcv
Prior art date
Application number
MX2018000213A
Other languages
English (en)
Inventor
M Awni Walid
M Bernstein Barry
C Brun Scott
E Cohen Daniel
J Podsadecki Thomas
Dutta Sandeep
M Menon Rajeev
A Vilchez Regis
Khatri Amit
Mensing Sven
O Dumas Emily
E Klein Cheri
BAYKAL Tolga
X Rodrigues Lino Jr
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2018000213A publication Critical patent/MX2018000213A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención presenta terapias sin interferón para el tratamiento del VHC genotipo 1b, 2, 3 o 4. En un aspecto, las terapias comprenden la administración de Compuesto 1 (Paritaprevir), Ritonavir y Compuesto 2 (Ombitasvir) a un sujeto infectado con VHC genotipo 1b o 4, en donde las terapias no incluyen la administración de ningún interferón, y las terapias duran de 8 a 12 semanas. Preferentemente, las terapias no incluyen la administración de ninguna ribavirina.
MX2018000213A 2015-06-29 2016-06-28 Metodos para tratar el vhc. MX2018000213A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562186185P 2015-06-29 2015-06-29
US201562267623P 2015-12-15 2015-12-15
PCT/US2016/039838 WO2017004053A1 (en) 2015-06-29 2016-06-28 Methods for treating hcv

Publications (1)

Publication Number Publication Date
MX2018000213A true MX2018000213A (es) 2018-03-14

Family

ID=57608995

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000213A MX2018000213A (es) 2015-06-29 2016-06-28 Metodos para tratar el vhc.

Country Status (9)

Country Link
US (1) US20180177778A1 (es)
EP (1) EP3313398A4 (es)
JP (1) JP2018519306A (es)
CN (1) CN107921020A (es)
AU (1) AU2016285578A1 (es)
BR (1) BR112017028488A2 (es)
CA (1) CA2990965A1 (es)
MX (1) MX2018000213A (es)
WO (1) WO2017004053A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110675961A (zh) * 2019-08-13 2020-01-10 中南大学 一种估算齐多夫定药时曲线下面积的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104023726A (zh) * 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如，与abt-072或abt-333)
US8492386B2 (en) * 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) * 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8853176B2 (en) * 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
JP2016523924A (ja) * 2013-07-02 2016-08-12 アッヴィ・インコーポレイテッド Ｈｃｖの治療方法

Also Published As

Publication number Publication date
WO2017004053A1 (en) 2017-01-05
CN107921020A (zh) 2018-04-17
EP3313398A4 (en) 2019-03-27
US20180177778A1 (en) 2018-06-28
EP3313398A1 (en) 2018-05-02
BR112017028488A2 (pt) 2018-08-28
JP2018519306A (ja) 2018-07-19
AU2016285578A1 (en) 2018-01-25
CA2990965A1 (en) 2017-01-05

Similar Documents

Publication Publication Date Title
MX2015017953A (es) Metodos para tratar el virus de hepatitis c.
MX2020005054A (es) Combinacion de dos agentes antivirales para el tratamiento de hepatitis c.
MX2016012799A (es) Metodos para tratar el virus de la hepatitis c.
PH12014502848A1 (en) Methods for treating hcv comprising at least two direct acting antiviral agent, ribavirin but not interferon
MX2015012536A (es) Combinacion de agentes antivirales de accion directa y ribavirina para el tratamiento de pacientes con vhc.
PH12019500513A1 (en) Mast cell stabilizers for treatment of hypercytokinemia and viral infection
RU2015114543A (ru) Способы лечения гепатита с
BR112018000383A2 (pt) métodos para tratar hcv
MX2020002605A (es) Terapias de combinacion de individuos infectados con virus de la hepatitis b (vhb) usando parapoxvirus ovis (ppvo) y al menos un farmaco antivirico adicional.
MX2016012722A (es) Metodos para tratar el virus de la hepatitis c.
WO2016014527A3 (en) Stabilized nucleotides for medical treatment
MX2018014377A (es) Metodos para tratar infecciones por virus de hepatitis b usando inhibidores de proteina no estructural 5a (ns5a), proteina no estructural 5b (ns5b) o proteina no estructural 3 (ns3).
PH12017500820A1 (en) Combination long acting compositions and methods for hepatitis c
PH12017500817A1 (en) Long acting pharmaceutical compositions for hepatitis c
MX2018000213A (es) Metodos para tratar el vhc.
EA201692514A1 (ru) Фармацевтические композиции на основе софосбувира и рибавирина с модифицированным высвобождением
MY191506A (en) Dosage regimen for pegylated interferon
EA201692507A1 (ru) Фармацевтические комбинации софосбувира и рибавирина
EA201692515A1 (ru) Новая фармацевтическая композиция на основе софосбувира и рибавирина
Kravchenko et al. Effect of HIV infection‐related factors on SVR rate in HCV treatment in HIV‐infected patients
Boglione Ribavirin/telaprevir interaction
EA201491652A1 (ru) Средство для лечения вирусного гепатита с
EA202092602A2 (ru) -d-2'-дезокси-2'--фтор-2'--c-замещенные-2-модифицированные-n6-замещенные пуриновые нуклеотиды для лечения вызванных hcv заболеваний
MX2020001422A (es) Metodos para el tratamiento de hcv.
De Nicola Peginterferon-α-2a/ribavirin/telaprevir